Chester County News and Community Website
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development program at major scientific conferences, presenting data on the first 10 patients treated …
Cabaletta Bio Reveals Promising Clinical Data for Autoimmune Therapy Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) is set to unveil new clinical data on its investigational therapy, CABA-201, at the American College of Rheumatology (ACR) Convergence 2024. The …
Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 Read More
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has broadened its collaboration with Moderna, Inc. (Nasdaq: MRNA) to focus on developing treatments for autoimmune diseases, marking a significant step in leveraging …
Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) recently issued a draft guidance aimed at improving the clinical development of drugs to treat pediatric patients with inflammatory bowel disease …
FDA Issues New Guidance for Pediatric Inflammatory Bowel Disease Drug Development Read More
WASHINGTON, D.C. — On Friday, the FDA approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for treating chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. This approval marks a significant development in …
FDA Approves New Treatment for Rare Nerve Disorder Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has released positive preliminary clinical data from its Phase 1/2 trials of CABA-201, a new potential treatment option for patients with autoimmune …
Cabaletta Bio Reports Promising Early Results for New Autoimmune Disease Treatment Read More
PHILADELPHIA, PA — In a notable push into the autoimmune diseases arena, Century Therapeutics has announced key developments in its iPSC-derived iNK cell therapy, CNTY-101. The company is looking to …
Century Therapeutics Gears Up to Conquer Highly Unmet Areas in Autoimmune Disease Treatments Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to its investigational therapy, CABA-201. This designation …
Cabaletta Bio Receives FDA Orphan Drug Designation for Innovative Autoimmune Disease Therapy Read More